In 1996, the Barcelona group demonstrated the presence of clinically significant portal hypertension (PHTN), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, to be the most powerful predictor of post‐operative liver decompensation and, in a subsequent (1999) publication, of poor long‐term outcome in Child–Pugh A cirrhotic patients submitted to hepatic resection (HR).
1. x 1. Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., and Garcia‐Pagan, J.C. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996; 111: 1018–1022 Abstract | Full Text PDF | PubMed | Scopus (605) | Google Scholar See all References
, 2. x 2. Llovet, J.M., Fuster, J., and Bruix, J. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30: 1434–1440 Crossref | PubMed | Scopus (1283) | Google Scholar See all References However, measurement of HVPG is invasive and requires technical expertise, whereas other clinical parameters are more easily evaluated.
3 x 3. De Franchis, R., Dell'Era, A., and Primignani, M. Diagnosis and monitoring of portal hypertension. Dig Liver Dis. 2008; 40: 312–317 Abstract | Full Text | Full Text PDF | PubMed | Scopus (38) | Google Scholar See all References Indeed, the presence of oesophageal varices as determined by endoscopy or significant splenomegaly (major diameter >12 cm) with a platelet count of <100 000/mm
3 are considered surrogate markers of clinically significant PHTN, regardless of portal pressure measurements.
4 x 4. Bruix, J. and Sherman, M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208–1236 Crossref | PubMed | Scopus (4202) | Google Scholar See all References As a consequence of these studies, the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines consider PHTN to be a relative contraindication to HR because of the high risk of post‐operative liver decompensation.
4. x 4. Bruix, J. and Sherman, M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208–1236 Crossref | PubMed | Scopus (4202) | Google Scholar See all References
, 5. x 5. Bruix, J. and Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020–1022 Crossref | PubMed | Scopus (4320) | Google Scholar See all References